Verona Pharma Plc ADR [VRNA] stock prices are up 0.28% to $106.69 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRNA shares have gain 0.40% over the last week, with a monthly amount glided 0.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on July 14, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Wolfe Research started tracking the stock with Outperform rating on July 01, 2025, and set its price target to $170. On April 28, 2025, TD Cowen initiated with a Buy rating and assigned a price target of $100 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $80 on April 21, 2025. ROTH MKM initiated its recommendation with a Buy and recommended $68 as its price target on January 10, 2025. Wells Fargo started tracking with a Overweight rating for this stock on October 03, 2024, and assigned it a price target of $50.
The stock price of Verona Pharma Plc ADR [VRNA] has been fluctuating between $27.54 and $106.45 over the past year. Currently, Wall Street analysts expect the stock to reach $129.25 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $106.69 at the most recent close of the market. An investor can expect a potential return of 21.15% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.25%, Pretax Profit Margin comes in at -0.33%, and Net Profit Margin reading is -0.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.39 and Total Capital is -0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 106.62 points at the first support level, and at 106.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 106.76, and for the 2nd resistance point, it is at 106.82.
Ratios To Look Out For
It’s worth pointing out that Verona Pharma Plc ADR [NASDAQ:VRNA]’s Current Ratio is 10.71. In addition, the Quick Ratio stands at 10.54 and the Cash Ratio stands at 8.55. Considering the valuation of this stock, the price to sales ratio is 41.16, the price to book ratio is 32.97.
Transactions by insiders
Recent insider trading involved Cunningham Kenneth, Director, that happened on Aug 01 ’25 when 10808.0 shares were sold. Director, Deschamps Lisa completed a deal on Aug 01 ’25 to sell 9464.0 shares. Meanwhile, General Counsel Fisher Andrew sold 9584.0 shares on Aug 01 ’25.
